WASHINGTON – Today, the nonprofit Institute for Patient Access made the following statement regarding the Institute for Clinical and Economic Review’s (ICER) evidence report on the value of new, innovative treatments for migraine known as CGRP inhibitors.
STATEMENT FROM BRIAN KENNEDY, EXECUTIVE DIRECTOR, INSTITUTE FOR PATIENT ACCESS:
“ICER appropriately recognizes the value of groundbreaking therapies for migraine patients in its evidence report. But this conclusion does not change the fact that ICER’s underlying methodology remains deeply flawed. For this ICER report, the group’s economists once again have relied upon incomplete data to drive a once-size-fits-all valuation of innovative medicine.
Migraine patients, and all patients, deserve an approach that more accurately incorporates the variables that characterize patients’ unique disease experiences and comorbidities.”